A detailed history of Price T Rowe Associates Inc transactions in Longboard Pharmaceuticals, Inc. stock. As of the latest transaction made, Price T Rowe Associates Inc holds 2,217,995 shares of LBPH stock, worth $60 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares
2,217,995
Previous 1,626,982 36.33%
Holding current value
$60 Million
Previous $9.81 Million 388.28%
% of portfolio
0.01%
Previous 0.0%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 15, 2024

BUY
$18.89 - $26.06 $11.2 Million - $15.4 Million
591,013 Added 36.33%
2,217,995 $47.9 Million
Q4 2023

Feb 14, 2024

SELL
$3.68 - $6.5 $534,946 - $944,879
-145,366 Reduced 8.2%
1,626,982 $9.81 Million
Q3 2023

Nov 14, 2023

BUY
$5.49 - $7.49 $444,788 - $606,824
81,018 Added 4.79%
1,772,348 $9.86 Million
Q2 2023

Aug 14, 2023

BUY
$4.19 - $10.05 $949,269 - $2.28 Million
226,556 Added 15.47%
1,691,330 $12.4 Million
Q1 2023

May 15, 2023

SELL
$3.84 - $5.96 $177,358 - $275,274
-46,187 Reduced 3.06%
1,464,774 $5.76 Million
Q4 2022

Feb 14, 2023

BUY
$3.21 - $5.5 $3,807 - $6,523
1,186 Added 0.08%
1,510,961 $4.78 Million
Q3 2022

Nov 14, 2022

SELL
$2.95 - $4.7 $5,793 - $9,230
-1,964 Reduced 0.13%
1,509,775 $5.62 Million
Q2 2022

Aug 15, 2022

SELL
$2.96 - $5.38 $1,480 - $2,690
-500 Reduced 0.03%
1,511,739 $4.67 Million
Q1 2022

May 16, 2022

SELL
$4.0 - $6.0 $2.05 Million - $3.07 Million
-512,377 Reduced 25.31%
1,512,239 $7.85 Million
Q4 2021

Feb 14, 2022

SELL
$4.75 - $9.45 $1.24 Million - $2.46 Million
-260,674 Reduced 11.41%
2,024,616 $9.8 Million
Q3 2021

Nov 15, 2021

SELL
$8.65 - $11.36 $17,291 - $22,708
-1,999 Reduced 0.09%
2,285,290 $20.4 Million
Q2 2021

Aug 16, 2021

SELL
$7.95 - $17.3 $122,907 - $267,458
-15,460 Reduced 0.67%
2,287,289 $20.1 Million
Q1 2021

May 17, 2021

BUY
$16.0 - $16.89 $36.8 Million - $38.9 Million
2,302,749 New
2,302,749 $36.2 Million

Others Institutions Holding LBPH

About Longboard Pharmaceuticals, Inc.


  • Ticker LBPH
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 13,586,000
  • Market Cap $367M
  • Description
  • Longboard Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing transformative medicines for neurological diseases. The company's lead product candidate is LP352, which is in a Phase 1b/2a clinical trial for the treatment of seizures associated with developmental and epileptic encephalopathies. Its preclinical ...
More about LBPH
Track This Portfolio

Track Price T Rowe Associates Inc Portfolio

Follow Price T Rowe Associates Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Price T Rowe Associates Inc , based on Form 13F filings with the SEC.

News

Stay updated on Price T Rowe Associates Inc with notifications on news.